Hotbed/Location

Found 598,932 articles

• Steven Tuch Joins Rallybio to Lead Corporate Development

  1/21/2021

  Rallybio LLC, a clinical-stage biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced the hiring of Steven Tuch to lead the Company’s corporate development function. In this role, Mr. Tuch, a seasoned healthcare business professional, will have responsibility for Rallybio’s financing

• Kuur Therapeutics Announces Interim Clinical Data Supporting CAR-NKT Cell Therapy Platform

  1/21/2021

  Kuur Therapeutics, the leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies, today announced clinical updates for both the phase 1 GINAKIT2 study of KUR-501 (autologous GD2 CAR-NKT cells) being tested in patients with relapsed/refractory (R/R) neuroblastoma,

• IMBiotechnologies Ltd. Announces Agreement with Canadian Hospital Specialties to Distribute Ekobi® Embolization Microspheres in Canada

  1/21/2021

  IMBiotechnologies Ltd. (“IMB” or the “Company”) today announced that it has signed an agreement with Canadian Hospital Specialties (“CHS”) for the exclusive right to distribute Ekobi® Embolization Microspheres (“Ekobi”) in Canada. “CHS has expertise in the distribution of a broad range of medical d

• CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research

  1/21/2021

  Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the publication of results from the CAPLYTA clinical trial (ITI-007-303) in adult patients with schizophrenia.

• electroCore, Inc. Announces Scottish Health Technology Group Recommendation For Use of gammaCore™ in NHS Scotland Cluster Headache Patients

  1/21/2021

  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Health Improvement Scotland (“HIS”) has published a Scottish Health Technology Group (“SHTG”) adaptation for NHS Scotland on the use of gammaCore for cluster headache.

• VBI Vaccines Announces Progress of Coronavirus Vaccine Program

  1/21/2021

  VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today provided an update on the progress of its coronavirus vaccine program, consisting of two vaccine candidates

• Viz.ai’s Viz RECRUIT Software Enables Faster Medical Research

  1/21/2021

  Viz.ai has announced the launch of Viz RECRUIT , cutting edge software that uses artificial intelligence to accelerate clinical studies. Viz RECRUIT uses AI to automatically detect a suspected disease such as a brain hemorrhage, a tumor, or a cardiac structural abnormality, and uses that insight to ensure the right doctor is notified abo

• VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company

  1/21/2021

  VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the execution of a contract with a major PBM for its novel AMZEEQ® (minocycline) topical foam, 4% and ZILXI® (minocycline) topical foam, 1.5%

• Newron Completes Enrollment of Explanatory Safety and Efficacy Study With Evenamide in Schizophrenia Patients

  1/21/2021

  Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the completion of enrollment for its explanatory study

• Avicanna Initiates Pre-Clinical and Behavioural Studies on its RHO Phyto™ Formulary with University of Guelph and Provides Research and Management Team Updates

  1/21/2021

  Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products has updated and amended its collaboration with Dr. Jibran Khokhar, Assistant Professor at the University of Guelph, and initiated prioritized pre-clinical studies on the RHO Phyto formulations that are commercialized in Canada and Colombia.

• Argos Cardiac Output Monitor Earns CE Mark Approval

  1/21/2021

  Retia Medical, a leading provider of minimally-invasive hemodynamic monitoring technology today announced it received CE (Conformitè Europëenne) Mark approval for its Argos Cardiac Output Monitor.

• Greenwich LifeSciences to Present at B. Riley Securities and BIO CEO & Investor Conferences

  1/21/2021

  Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced that Snehal Patel, CEO of Greenwich LifeSciences, will participate in the following upcoming virtual investor conferences, highlighting the Company’s GP2 Phase IIb trial data and the planned Phase III trial.

• numares and Bruker Sign Agreement to Enable Advanced Metabolomics-based Clinical Diagnostics

  1/21/2021

  Leading metabolomics based diagnostics company numares AG and analytical instrumentation and solution provider Bruker Corporation have signed an agreement to collaborate to bring new diagnostics tests utilizing NMR to the laboratory market for unmet medical needs.

• CureLab Oncology Launches Veterinary Oncology Subsidiary, CureLab Veterinary

  1/21/2021

  Based on a scientifically solid proof of concept in dogs and cats, an international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding campaign set to launch within a month, and to become profitable within 36 months of raising funds.

• AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients

  1/21/2021

  AriBio Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, announced , 21st of January 2021, the completion of last patient last visit in a Phase 2 study of AR1001.

• OraSure’s Oragene®•Dx Saliva Collection Kit Included in Industry’s First FDA Authorization for a Whole Exome Sequencing Platform

  1/21/2021

  OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that its Oragene®•Dx saliva collection device was included as a component in the De Novo authorization granted by the U.S. Food & Drug Administration to Helix for their Helix® Laboratory Platform1, a whole exome sequencing platform.

• Ravi Deshpande joins ELNA Medical as Chief Business Development Officer, Canada

  1/21/2021

  management team at ELNA Medical is delighted to welcome Ravi Deshpande as Chief Business Development Officer, Canada.

• Relief Announces Implementation of New Share Subscription Facility with Main Shareholder GEM

  1/21/2021

  RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat severe COVID-19 patients, announced that it has signed a binding agreement with the Company's main shareholder GEM Global Yield LLC SCS for the implementation of a new Share Subscription Facility in the amount of up to CHF 50 million.

• Sapreme Appoints Henrik Luessen as Chief Business Officer

  1/21/2021

  Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, announced the appointment of Henrik L. Luessen, Ph.D., as Chief Business Officer.

• ViaDerma, Inc. Completes a Licensing Agreement with a Group of Affiliate Wound Care Medical Practices Operating in Six States

  1/21/2021

  ViaDerma, Inc., announces the completion of a licensing agreement with a group of affiliated wound care medical practices.